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Abstract 
Background 
Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first 
line treatment of aHUS is plasma therapy, but in the past few years, the recommendations 
have changed greatly with the advent of eculizumab, a humanized monoclonal anti C5-
antibody. Although recent recommendations suggest using it as a primary treatment for 
aHUS, important questions have arisen about the necessity of immediate use of eculizumab in 
all cases. We aimed to draw attention to a specific subgroup of aHUS patients with rapid 
disease progression and high mortality, in whom plasma therapy may not be feasible. 
Methods 
We present three pediatric patients of acute complement-mediated HUS with a fatal outcome. 
Classical and alternative complement pathway activity, levels of complement factors C3, C4, 
H, B and I, as well as of anti-factor H autoantibody and of ADAMTS13 activity were 
determined. The coding regions of CFH, CFI, CD46, THBD, CFB and C3 genes were 
sequenced and the copy number of CFI, CD46, CFH and related genes were analyzed. 
Results 
We found severe activation and consumption of complement components in these patients, 
furthermore, in one patient we identified a previously not reported mutation in CFH 
(Ser722Stop), supporting the diagnosis of complement-mediated HUS. These patients were 
not responsive to the FFP therapy, and all cases had fatal outcome. 
Conclusion 
Taking the heterogeneity and the variable prognosis of atypical HUS into account, we suggest 
that the immediate use of eculizumab should be considered as first-line therapy in certain 
small children with complement dysregulation. 
Keywords 
Atypical hemolytic uremic syndrome, Infant, Eculizumab, Plasma therapy 
Background 
Hemolytic uremic syndrome (HUS) defined by hemolytic anemia, thrombocytopenia, and 
acute renal failure belongs to the group of thrombotic microangiopathies (TMA) [1]. In the 
majority of cases Shiga toxin-producing bacteria cause HUS, which is also known as ‘typical’ 
HUS with a good prognosis and without relapses. However, less often the disease follows a 
relapsing course with high risk of permanent renal damage or even death [2,3]. In the 
majority of these cases with this ‘atypical’ HUS (aHUS), severe dysregulation of the 
alternative complement pathway can be detected, although, there are exceptions to this rule. 
Mutations, risk haplotypes, and copy-number variations in the genes encoding complement 
factors (such as complement factor H, membrane cofactor protein, complement factor I, 
complement C3, complement factor B or thrombomodulin) [1,2,4], and the presence of factor 
H autoantibodies [5] associated with the homozygous deletion of the complement factor H-
related gene 1 [6] have been described as predisposing factors for aHUS [1,2,4]. Much less is 
known about the pathogenesis of the non-complement-mediated forms of aHUS; however, a 
recent study, applying a next-generation sequencing-based approach has identified the 
variations of diacyl-glycerol kinase epsilon as a novel risk factor in such patients [7]. 
According to the 2009 guideline of the European Pediatric Study Group for HUS [3], the 
first-line treatment of atypical HUS – i.e. HUS not mediated by enterohaemorrhagic E. coli 
(EHEC), and not associated with Streptococcus pneumoniae – should be plasma therapy 
(plasma exchange or plasma infusions) with early assessment of the clinical response. 
However, in the past few years new prospects have opened in the management of aHUS with 
the advent of eculizumab. This humanized monoclonal anti C5-antibody, licensed for the 
treatment of patients with aHUS in the US in September 2011, and in the EU in November 
2011, inhibits C5, thereby preventing the generation of C5a and of the terminal complement 
complex C5b-9. Recently published clinical trials confirmed the efficacy and safety of 
eculizumab in plasma-dependent aHUS patients and in posttransplant aHUS recurrence [8,9], 
and a trial has been applied eculizumab as the first-line treatment of aHUS [10] The 
availability of eculizumab has increased noticeably during the past few years, and recent 
recommendations based on the above trials, case reports [11] and recent case series [12] 
suggest its administration as a primary treatment for patients with aHUS [13]. Recently, 
however, Ruebner and co-workers have raised an important question about the necessity of 
the immediate use of eculizumab in all aHUS cases [14]. The authors highlighted the 
heterogeneity of aHUS and described the illustrative case histories of three children aged less 
than 18 years with this condition. These patients proved responsive to plasma therapy and 
made full recovery. The authors recommended a stepwise approach to the management of 
patients with the aHUS phenotype, and suggested administering eculizumab only to patients 
likely to have an inherited, complement-mediated disorder and in cases without a good 
response to plasma therapy after 3–5 days. 
While agreeing with this opinion, we would like to draw attention to a specific subgroup of 
patients with rapidly progressive disease and a poor prognosis, in whom plasma exchange or 
effective plasma therapy may not be feasible due to young age and small body size. We 
review the cases of three infants to show that for such patients, prompt treatment with 
eculizumab would be indicated and urgent complement testing may guide immediate 
therapeutic decisions. 
Patients and methods 
Patient selection 
From January 2008 to June 2013, we investigated 5 patients under the age of 2 years with 
suspected atypical HUS (non-EHEC-mediated, non-pneumococcal disease). Blood samples 
obtained during the first acute phase were available from only three infants. 
In this study, we present case histories of these selected infants (a 7 month old boy from 
Kosovo, a newborn from Hungary, and a 2 month old girl from Austria) with complement 
mediated aHUS and fatal outcome during the first disease flare. Relevant clinical and 
laboratory data were collected from hospital records. The institutional review board of 
Semmelweis University approved the design of the study. 
Laboratory analysis 
Blood samples were collected during the first acute disease flare. Functional assessment of 
the activity of the alternative and classical complement pathways was performed along with 
the measurement of the concentrations of complement factors C3, C4, H, B and I, as well as 
of anti-factor H IgG autoantibodies, and of ADAMTS13 activity. These laboratory 
determinations have been described in detail elsewhere [15,16]. 
To measure the levels of factor H protein (as well as of CFHL-1 protein) variants containing 
tyrosine (p.Tyr402) or histidine (p.His402) at p.402, serum sample of patient 1 was tested 
with an allele-specific ELISA method using a HK353 ELISA kit (Hycult Biotech), according 
to the manufacturer’s instructions. 
To screen for mutations, all coding exons of the genes encoding complement factor H (CFH), 
factor I (CFI), membrane cofactor protein (CD46), thrombomodulin (THBD), factor B 
(CFB), C3 (C3) and diacyl-glycerol kinase epsilon (DGKE) were sequenced following PCR 
amplification. Primer sequences and PCR conditions are available upon request. 
To study the copy number alterations of the genes encoding complement factor H (CFH) and 
related genes (CFHR1, CFHR2, CFHR3, CFHR5), complement factor I (CFI) and membrane 
cofactor protein (CD46) multiplex ligation-dependent probe amplification (MLPA) was 
carried out by SALSA MLPA probemixes P236-A3 and P296-A1 (MRC-Holland, 
Amsterdam, The Netherlands) following the manufacturer’s instructions. 
Results 
Patient 1 
The male patient was born in Kosovo at week 39 of an uncomplicated pregnancy, with a birth 
weight of 3400 g. At the age of 7 months, he was taken to the Children’s Hospital in Prishtina 
due to sudden onset of pallor, weakness, and anemia. There was neither fever, nor diarrhea. 
His initial laboratory findings (see Table 1) showed severe anemia and thrombocytopenia 
with normal renal function and diuresis. Direct antiglobulin test was negative. 
Table 1 Laboratory findings at the time when aHUS was confirmed 
 Patient 1 Patient 2 Patient 3 
Age 7 months 2 days 2 months 
Gender Male Male Female 
Hemoglobin (g/L) 69 (120–160) 122 (100–160) 83 (120–150) 
Platelet count (G/L) 26 (150–400) 65 (130–450) 28 (140–440) 
LDH (U/L) 13500 (<500) 4826 (200–800) 5230 (100–300) 
Creatinine (μmol/L) 316 ( <88) 182 (20–105) 98 (8,8-88) 
Fragmentocytes + + - 
RBC transfusion (Unit) 6 times 2 times - 
Plasma therapy (number of sessions) FFP (6) FFP (9) FFP (1) 
Dialysis (sessions) 15 7 2 
Outcome Seizures, coma and respiratory failure, 
death on day 29 of hospitalization 
Pulmonary edema and pneumothorax, 
death on day 17 of hospitalization 
Cerebral edema, brain death on 
day 3 of hospitalization 
Comorbidities - Patent ductus arteriosus Colonic necrosis, coagulopathy 
Normal values are between brackets. 
He was initially considered to have sepsis and was given antibiotic treatment. He received 
packed red blood cells and fresh frozen plasma transfusions on three occasions. His 
hematological parameters improved, but on day 10 of hospitalization, his renal function 
deteriorated rapidly. He became anuric and decompensated dilated cardiopathy developed, 
which required hospitalization at the University Children’s Hospital Skopje, for peritoneal 
dialysis. 
Atypical HUS was suspected, but (after plasma therapy) his hematological parameters were 
inconclusive (haemoglobin level and platelet count were normal) on admission. Fragmented 
red blood cells could not be demonstrated even by repeated blood smear analysis, and 
complement C3 level was normal at 0.90 g/L. Peritoneal dialysis improved the patient’s 
clinical condition and cardiac function. His creatinine level peaked at 316 μmol/L. 
On day 19 of hospitalization, his overall condition worsened, severe anemia and seizures 
occurred. This time, blood smear analysis revealed many schistocytes. Follow-up laboratory 
tests confirmed the relapse of severe anemia and thrombocytopenia. At this point, the clinical 
diagnosis of atypical HUS was certain and appropriate blood samples were sent to Hungary 
for the comprehensive analysis of complement factors. These blood samples, received 24 
days after disease onset and after plasma therapy, were tested on the day of arrival of sample 
for C3, alternative pathway and ADAMTS13 activity, and the results indicated severe 
complement dysregulation. 
The patient was intubated and mechanically ventilated, transfused on three occasions with 
packed red blood cells and fresh frozen plasma. Despite intensive therapy and the 
administration of plasma, the baby fell into coma. Respiratory failure accompanied by 
symptomatic multiorgan failure led to the patient’s death on day 29 of hospitalization. 
Autopsy was not performed. 
Patient 2 
The male neonate was born in Hungary, from an uneventful pregnancy and delivered by the 
vaginal route, at 36 weeks of gestation, with a birth weight of 2150 g. 
On the second day of life, poor feeding, abdominal distension, hepatomegaly, respiratory 
distress were observed along with reduced skin perfusion and oliguria despite normal blood 
pressure. Bacterial sepsis was suspected and antibiotic treatment was introduced. 
The laboratory tests showed anemia, low platelet count, and metabolic acidosis, as well as 
bleeding disorder (increased INR; fibrinogen: under detection limit), and a marked elevation 
of LDH. However, no hyperbilirubinemia was present. On the 4
th
 day of life, uremia, low 
platelet count, and metabolic acidosis persisted, and moderate increase of alanine 
aminotransferase and aspartate aminotransferase levels were seen. Direct antiglobulin test 
was negative. 
Progressive circulatory failure required mechanical ventilation and catecholamine treatment 
from the 4
th
 day of life. Echocardiography depicted a haemodynamically significant, patent 
ductus arteriosus. The differential diagnosis excluded bacterial sepsis, renal vein thrombosis, 
and metabolic disorder. The treatment was supplemented with regular, periodic 
administration of fresh frozen plasma, based on the clinical signs and laboratory results 
indicative of aHUS. 
Progressive circulatory failure, oliguria and uremia culminated in extreme volume overload 
and pulmonary edema. Therefore, hemofiltration was started on the 9
th
 day of life and 
repeated altogether 7 times. Despite all these efforts, the patient did not improve and died on 
the 19
th
 day of life of circulatory failure unresponsive to the treatment. 
The serum complement profile obtained on day 14 showed alternative pathway dysregulation 
and supported the diagnosis of aHUS. Investigations during autopsy could not identify any 
alternative (infective or malignant) causes of HUS. The histological examination of the 
kidney and the lung revealed signs of small vessel microangiopathy (thickening of capillary 
walls, lamellation, detachment of endothelial cells, narrowing of the capillary lumen). 
Patient 3 
The female infant was born in Austria, at 38 weeks of gestation with a birth weight of 3750 g. 
The antenatal and the perinatal periods were uneventful. 
At the age of 2 months, she developed acute abdominal distension and cyanosis. There was 
no history of infection, vomiting, or diarrhea in the previous days. 
Initial laboratory findings included high LDH, CK, and serum transaminase levels. Serum 
albumin concentration was greatly reduced. INR, PTT, and thrombin time were prolonged, C-
reactive protein was normal; interleukin-8 level and the leukocyte count were elevated. Renal 
function parameters, platelet count, and hemoglobin were normal on day 1. 
Abdominal ultrasound showed massive edema of the bowels, particularly of the colon and the 
duodenum. A plain abdominal film did not depict any sign of free air. The progressive 
decline of oxygen saturation and worsening respiratory insufficiency necessitated respiratory 
support and then, intubation and mechanical ventilation. 
During the next hours, oliguria progressed to anuria, and generalised edema developed. 
Simultaneously, platelet count and hemoglobin level decreased, whereas renal function 
parameters increased. Peritoneal dialysis was initiated on day 2 due to progressive edema and 
renal insufficiency. The follow-up laboratory tests showed further elevation of the LDH level. 
Complement dysregulation was detected on day 2 (Table 2). The direct antiglobulin test was 
negative; haptoglobin level was decreased, and free hemoglobin concentration was increased 
in the plasma. These findings indicated intravasal hemolysis; however, fragmentocytes were 
absent from the blood smear. Irreversible multiorgan failure developed during the next hours; 
the CT scan confirmed generalized brain edema, while further testing excluded underlying 
infectious and/or metabolic causes of the multiorgan failure. The patient died on day 3. 
Table 2 Complement and genetic profiles of the members of the three affected families 
 Patient 1 Father 1 Mother 1 Sister 1 Patient 2 Father 2 Mother 2 Patient 3 Father 3 Mother 3 Brother 3 Sister 3 
Classical pathway activity CH50/mL (48–103) 47 n.d. n.d. n.d. 25 n.d. n.d. 0 n.d. n.d. n.d. n.d. 
Alternative pathway activity % (70–105) 5 88 97 108 0 71 77 0 106 110 70 72 
C3 g/L (0.9-1.8) 0.36 0.98 1.32 1.23 0.26 0.65 1.19 0.41 1.26 1.42 1.07 1.09 
C4 g/L (0.15-0.55) 0.23 n.d. n.d. n.d. 0.1 n.d. n.d. 0.05 n.d. n.d. n.d. n.d. 
Factor H:Ag mg/L (127–447) <95 378 813 631 123 369 549 <95 374 685 431 338 
Factor B % (70–130) 65 81 98 90 50 52 100 19 60 98 70 90 
Factor I % (70–130) 42 108 108 104 47 69 112 26 85 112 72 81 
Anti-factor H IgG autoantibody negative n.d. n.d. n.d. negative n.d. n.d. negative n.d. n.d. n.d. n.d. 
ADAMTS13 activity (67-151%) 27 214. 143 171 9 133 101 8 124 112 142 157 
ADAMTS13 inhibitor negative n.d n.d n.d n.d n.d n.d negative n.d n.d n.d n.d 
Mutation (Numbering from Met1) het CFH 
Ser722Stop 
het CFH 
Ser722Stop 
- - - - - - - - - - 
aHUS risk haplotypes het CFH H3; het 
MCPggaac 
het MCPggaac het CFH H3 het CFH H3 - - het CFH H3; 
het MCPggaac 
het MCPggaac hom MCPggaac het MCPggaac het MCPggaac het MCPggaac 
Missense variations het CFH Y402H; 
het CFH E936D; 
het C3 R102G; 
het C3 P314L; 
het CFB R32W 
hom CFH 
Y402H; het C3 
R102G; het C3 
P314L 
het CFH Y402H; 
het CFH E936D; 
het CFB R32W 
het CFH 
Y402H; het 
CFH E936D; 
hom CFH 
Y402H; het 
CFB R32W 
hom CFH 
Y402H; het 
CFB R32W 
het CFH 
Y402H; het 
CFH E936D; 
hom CFH 
Y402H; het C3 
R102G; het C3 
P314L; het 
CFB L9H 
het CFH V62I, 
het CFH Y402H; 
hom C3 R102G; 
hom C3 P314L; 
het CFB L9H 
hom CFH 
Y402H; het 
CFB R32Q 
het CFH V62I, 
het CFH Y402H; 
het C3 R102G; 
het C3 P314L; 
het CFB R32Q 
hom CFH 
Y402H; het 
C3 R102G; 
het C3 P314L 
Abbreviations used: het heterozygous, hom homozygous, n.d. not determined, bold characters indicate values below the reference range. 
Investigations during autopsy could not identify any alternative (infective or malignant) 
causes of HUS. The histological examination of the kidney, spleen, lung, bowel, and 
myocardium confirmed thrombotic microangiopathy. 
The results of complement- and genetic testing 
The detailed results of complement profiling are presented in Table 2. Alternative 
complement pathway activity was decreased in all three patients. The consumption of C3, as 
well as decreased levels of complement factor B and I were found in all cases. Factor H level 
was below the detection limit in patient 1 and 3, and it was decreased in patient 2. The level 
of C4 and the activity of the classical pathway were decreased in patients 2 and 3. Since we 
observed unusual concomitant decrease in these factors in patients 2 and 3, we have 
measured the levels of potassium, magnesium, calcium and phosphate in these serum samples 
and none of them was decreased excluding the possibility that samples were diluted with 
infusion. 
ADAMTS13 activity was decreased but not deficient in all cases, and the presence of the 
ADAMTS13 inhibitor was excluded in two cases (Table 2). None of the family members had 
low (<67%) ADAMTS13 level indicative of ADAMTS13 deficiency. We suspect secondary 
ADAMTS13 consumption by the ultra-large von Willebrand factor due to extensive 
endothelial activation. 
All patients were negative for anti-factor H autoantibody. Regarding the family members of 
patients, no signs of complement deficiency or dysregulation was detected in the family of 
patient 1. The father of patient 2 had low levels of factor B, I and C3, the father of patient 3 
had below normal level of factor B, while other family members in these families had normal 
complement parameters. 
To investigate the genetic alterations in our patients, we sequenced the coding regions of 
complement genes CFH, CFI, CD46, THBD, CFB, C3 and DGKE. Patient 1 was 
heterozygous for a cytosine to adenine substitution (c.2165C>A) in exon 15 of CFH 
(encoding short consensus repeat 12) that causes a serine to STOP change at p.722 
(Ser722Stop) in the protein. Mutation at this site has not been reported previously. Based on 
the analysis of inheritance in the patient’s family, this mutation was located on an allele 
coding histidine at p.402. As the patient was heterozygous for the Tyr402His (Y402H) 
polymorphism, we applied an ELISA test system using two different monoclonal antibodies, 
specific for the His402- and Tyr402- containing factor H proteins (HK353 ELISA kit, Hycult 
Biotech). The level of factor H protein from the Ser722Stop mutation-containing allele 
(p.402His-containing factor H) was below the lower limit of quantification, while the level of 
factor H from the other allele (p.402Tyr-containing factor H) was low, but still measurable in 
the serum sample of the patient. The mutation-carrying father of the patient was not 
heterozygous for the Tyr402His polymorphism, therefore there are no comparable alleles in 
his serum, so we did not apply this method in this case. Based on these results we concluded 
that the mutation p.Ser722Stop by causing the premature termination of translation 
presumably leads to deficient synthesis and/or secretion of the mutated protein. No disease-
causing mutation was detected in the other two patients. 
Sequencing of the selected complement genes revealed the presence of multiple polymorphic 
variants. As inferred from genotype data, one patient (patient 1) carried the H3 risk haplotype 
of the CFH gene, and two patients (patient 1 and patient 3) carried risk alleles of MCP 
polymorphisms (MCPggaac). The results of the pedigree analysis are presented in Table 2. 
To reveal deletions or duplications that may influence disease development, CFI, CD46 
(MCP) as well as CFH and its related genes were studied by applying MLPA probemixes of 
MRC-Holland. None of the patients showed copy number alterations in the selected genes. 
Discussion 
Recent findings on the pathogenesis and the new therapeutic options have markedly changed 
the recommendations on the initial investigations and therapy of choice in aHUS. However, a 
number of questions remain open regarding the optimal management of patients with aHUS 
[17]. We presented this small series of three patients with acute complement-mediated HUS 
to highlight a specific subgroup of infants characterized by rapid disease progression and 
high mortality, as well as to pinpoint the important aspects of the clinical management of 
these cases. 
The classification of HUS as atypical HUS is based on the clinical signs (see the 2009 
guideline), and the recognition of HUS in the context of sepsis or disseminated intravascular 
coagulation is often delayed, because anemia and thrombocytopenia are characteristic of both 
diseases. Plasma therapy may interfere with the laboratory tests used to support aHUS and 
can thereby delay correct diagnosis. However, initial complement results may be helpful and 
these can be obtained within 1–2 days. According to the Clinical Practice Guidelines for the 
management of aHUS [3], detailed complement investigation is recommended in all cases at 
the onset of the episodes, before administering plasma therapy. To explore the complement-
related pathogenetic factors, it is suggested to test the serum levels of C3, C4 (for differential 
diagnosis), factor I and factor H, as well as of autoantibodies to factor H and MCP expression 
on leukocytes. The genetic analysis of selected complement factors should also be performed. 
During the recent years, we added two more tests to the diagnostic evaluation of the 
alternative complement pathway, i.e. the measurement of total AP activity, and of factor B 
level. According to our previous results [18], multiple assessment of the components and 
total activity of the alternative pathway (decreased C3, factor B and alternative pathway 
activity) appears to yield specific information on complement-mediated processes in aHUS. 
In this small series of cases with clinically diagnosed aHUS, all patients had decreased 
alternative pathway activity with consumption of factors C3 and B, as well as with unusually 
low levels of factors H and I, indicating extensive amplification and consumption of the 
alternative pathway with its regulators. In our opinion, all three patients had complement-
mediated HUS, as all of them presented with hemolytic anemia, thrombocytopenia and acute 
renal failure (Figure 1). Moreover, severe dysregulation and consumption of the alternative 
complement pathway could be verified within a day after the arrival of the blood sample to 
the laboratory. It should be noted, however, that the marked decrease of classical pathway 
activity, C4 levels, and ADAMTS13 activity in our cases indicates an uncommon 
pathogenetic mechanism (most likely induced by yet unidentified genetic predisposing 
factors in cases 2 and 3). Low but not deficient ADAMTS13 level of patients besides the 
absence of ADAMTS13 inhibitors (where measured) excluded the diagnosis of TTP, while 
based on the normal levels of ADAMTS13 activity of the healthy family members we ruled 
out the possibility of Upshaw-Schulman syndrome. Furthermore, unidentified, alternative 
causes of HUS, such as infectious, malignant, immunologic, or metabolic diseases may also 
be suspected in our patients. However, the fact that no such diseases were found during 
autopsy in patients 2 and 3, renders this possibility improbable. The findings of the 
histological investigations performed during autopsy supported the diagnosis of TMA in 
patients 2 and 3. Therefore we consider that complement mediated HUS was the primary 
diagnosis in these cases. Since signs of coagulation disorder were also present disseminated 
intravascular coagulation accompanied aHUS in patients 2 and 3. 
Figure 1 Development of symptoms and laboratory signs of aHUS during the course of 
disease in the three patients. Abbreviation used: PRBC: packed red blood cells; FFP: Fresh 
frozen plasma; C3: Complement C3. (Microsoft Office PowerPoint 97–2003 was used to 
create the artwork). 
Analyzing the predisposing genetic components within complement factors, we identified 
combined risk factors (factor H mutation Ser722Stop and two risk haplotypes in CFH and 
MCP) for patient 1, and non-synonymous SNPs (in C3 or CFB) and/or aHUS risk haplotype 
(MCPggaac) for patients 2 and 3. In approximately 40-50% of aHUS cases, no mutations can 
be identified in the complement genes [2,19]. The missense polymorphisms of C3 
(rs2230199: R102G, rs1047286: P314L) and factor B (rs4151667: L9H and rs12614: R32W) 
identified in the patients has unknown significance in aHUS. However, carriers of the rare 
alleles of the R102G SNP and of the P314L polymorphism as well as of their haplotype were 
reported to have lower AP50 values (higher alternative pathway activity) than those with 
homozygous wild genotypes [20]. In agreement with this, in hemolysis assays G102 activated 
the alternative pathway more efficiently and had higher hemolytic activity compared with the 
R102 C3 protein as in the presence of glycine at p.102 the efficiency of factor H as a cofactor 
in C3b inactivation was reduced [19]. Since decreased levels of complement parameters 
(predominantly factor B) were observed in healthy family members (i.e. in the father of 
patients 2 and 3), we suspect additional predisposing genetic variants in the background of 
the disease [4]. 
Since the publication of the “European Guideline for the investigation and initial therapy of 
HUS” significant progress has been made in the therapy of HUS with the clinical verification 
of the efficacy of eculizumab [8], an anti-C5 monoclonal antibody based inhibitor of the 
complement terminal pathway. Physicians treating patients with atypical HUS have to choose 
between plasma therapy and eculizumab for the initial treatment of acute disease. 
Although the guidelines recommend plasma exchange [1,3], low total blood volume and 
difficult vascular access make plasmapheresis technically challenging in infants; therefore, 
this therapeutic option is seldom used [21,22]. Fresh frozen plasma transfusion is an 
alternative option, but this treatment will not eliminate potentially harmful components and 
as in our cases, patients often do not respond to FFP. Moreover, mortality rate appears to be 
the highest in patients under 2 years [19,23]. Based on a recent paper, there were 9 cases with 
fatal outcome and 6 of them were under 2 years of age in the French cohort. In the Dutch 
cohort, only the youngest patient in the study, a one month old baby died during the first 
aHUS episode. In accordance with these data, we have also observed a high mortality rate in 
this age group: altogether 4 of our 5 infant patients died under the age of 1 (unpublished 
data). 
We report these patients to draw attention to a plasma-resistant disease subtype with a severe 
outcome in infants. We believe that eculizumab might have saved the lives of our patients, 
but this therapy could not be started fast enough in our cases due to its high price (in 
Hungary), its unavailability (in Macedonia), or because of the rapid progression of disease (in 
Austria). Previously, other reports confirmed that eculizumab could be an effective therapy 
for infants with aHUS of rapidly progressive onset, when plasmapheresis is not feasible 
[10,24-26]. In agreement with these recommendations [10,17,26], we also suggest that 
eculizumab should be the first-line therapy for infants with hypocomplementemia 
accompanied by the clinical symptoms of aHUS. Treatment should start immediately when 
clinical diagnosis of HUS can be verified and the atypical form is suspected [3]. A recently 
published paper proposed a stepwise approach for the management of aHUS [14]. This would 
be appropriate for most patients; however, in the case of infants, we would not be willing to 
wait 3–5 days to assess the patient’s response to plasma therapy. Urgent investigation of the 
alternative complement pathway is appropriate to stratify patients for eculizumab therapy. 
Therefore, in agreement with a recent recommendation [17], we would suggest prompt 
treatment with eculizumab in small pediatric cases, once complement dysregulation has been 
recognized. 
Conclusion 
Infants constitute a specific subgroup of atypical HUS patients, with rapid disease 
progression and high mortality, in whom plasma therapy may not be feasible. The use of 
eculizumab should be considered as first-line therapy in these pediatric cases. Urgent 
investigation of the alternative complement pathway is suitable to stratify patients for 
eculizumab therapy. We would suggest that the treatment should start immediately, once the 
diagnosis of HUS has been verified and the atypical form is suspected. 
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